The second one is amivantamab-vmjw (Rybrevant®), which targets epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET) and can be used in the treatment of non-small cell lung cancer (NSCLC) [207]. This evidence concerns the gene MET and non-small cell lung carcinoma.